IRIX - イリデックス （IRIDEX Corporation） イリデックスIRIXのチャート
IRIXの企業情報
| symbol | IRIx |
|---|---|
| 会社名 | IRIDEX Corp. （イリデックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Electromedical_Electrotherapeutic Apparatus |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 イリデックス（IRIDEX Corporation）は眼科学における目の疾患の治療用の治療ベースのレーザーシステム、送達デバイス及び消耗器具のグローバルなプロバイダー。同社は主に眼科に集中する。同社の眼科治療商品は主に直販の方式で米国内に販売されて、100カ国以上における約70の独立系代理販売業者を介して国際的に販売される。同社の眼科治療商品は「IQ」と「OcuLight」レーザーシステム、消耗品、及びサービスと支援業務を含む。同社の「IQ」製品群は「IQ 532」、「IQ 577」と「IQ 810」のレーザー光凝固システムを含み、「OcuLight」商品は「OcuLight TX」、「OcuLight Symphony」（レーザー・デリバリー・システム）、「OcuLight SL」、「OcuLight SLx」、「OcuLight GL」及び「OcuLight GLx」のレーザー光凝固システムを含む。平成24年2月、同社はCutera Inc.に美容事業を譲渡した。 イリデックスは医療用レ―ザ―システムを提供する米国企業。眼疾患治療に使用されるレ―ザ―システム、送達デバイス及び消耗器具類などを開発、製造。糖尿病性網膜症、緑内障、加齢性黄斑変性症などの視力を脅かす眼の疾患を対象とする。販売代理店を通じて、世界的に製品を販売。本社はカリフォルニア州。 Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company's proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex's current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. |
| 本社所在地 | 1212 Terra Bella Avenue Mountain View CA 94043-1824 USA |
| 代表者氏名 | William M. Moore ウィリアム・M・ムーア |
| 代表者役職名 | Chairman of the Board Interim President and Chief Executive Officer |
| 電話番号 | +1 650-940-4700 |
| 設立年月日 | 32540 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1996年 |
| 従業員数 | 154人 |
| url | www.iridex.com |
| nasdaq_url | https://www.nasdaq.com/symbol/irix |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -14.49200 |
| 終値（lastsale） | 5.925 |
| 時価総額（marketcap） | 69110260.575 |
| 時価総額 | 時価総額（百万ドル） 69.31863 |
| 売上高 | 売上高（百万ドル） 40.92100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 53.27363 |
| 当期純利益 | 当期純利益（百万ドル） -15.13400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 IRIDEX Corporation revenues decreased 3% to $19.8M. Net loss increased 49% to $6.9M. Revenues reflect United States segment decrease of 14% to $10M Asia/Pacific Rim segment decrease of 2% to $3.9M. Higher net loss reflects Selling/General/Admin. Expense increase of 26% to $8M (expense) Selling expenses increase of 25% to $4.4M (expense). |
IRIXのテクニカル分析
IRIXのニュース
Iridex''s Cyclo G6 platform for treating glaucoma gets regulatory clearance in China 2022/06/14 14:02:34 Seeking Alpha
Iridex (IRIX) on Tuesday said it had got Chinese regulatory clearance to market and sell its Cyclo G6 platform for the treatment of glaucoma diseases.IRIX and its distribution…
Iridex Obtains Regulatory Clearance for Cyclo G6® Glaucoma Platform in China 2022/06/14 13:21:00 GlobeNewswire
MOUNTAIN VIEW, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced that it has received regulatory clearance to market and sell its Cyclo G6 ® platform for the treatment of glaucoma diseases in China by its National Medical Products Administration (NMPA). In accordance with the clearance, Iridex and distribution partners Topcon and Clinico will launch the Cyclo G6 system and related probes in China beginning in the third quarter of 2022.
Iridex Obtains Regulatory Clearance for Cyclo G6 Glaucoma Platform in China 2022/06/14 13:21:00 Wallstreet:Online
MOUNTAIN VIEW, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced that it has received regulatory clearance to market and sell its Cyclo G6 platform for the treatment of glaucoma diseases in China by its National Medical Products Administration
Rate - IRIDEX Stock Rating Upgraded by Zacks Investment Research 2022/06/02 06:09:08 Business Mag
IRIDEX was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks…
IRIDEX Corporation''s (IRIX) CEO David Bruce on Q1 2022 Results - Earnings Call Transcript 2022/05/13 02:06:05 Seeking Alpha
IRIDEX Corporation (NASDAQ:NASDAQ:IRIX) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants David Bruce – Chief Executive Officer Hunter Cabi – Investor Relations…
Rate - IRIDEX Stock Rating Upgraded by Zacks Investment Research 2022/06/02 06:09:08 Business Mag
IRIDEX was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks…
IRIDEX Corporation''s (IRIX) CEO David Bruce on Q1 2022 Results - Earnings Call Transcript 2022/05/13 02:06:05 Seeking Alpha
IRIDEX Corporation (NASDAQ:NASDAQ:IRIX) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants David Bruce – Chief Executive Officer Hunter Cabi – Investor Relations…
IRIDEX GAAP EPS of -$0.15 beats by $0.01, revenue of $13.39M misses by $0.02M 2022/05/12 20:27:42 Seeking Alpha
IRIDEX press release (IRIX): Q1 GAAP EPS of -$0.15 beats by $0.01.Revenue of $13.39M (+12.0% Y/Y) misses by $0.02M.Guidance for Full Year 2022:Total revenue for the full year…
Iridex Announces First Quarter 2022 Financial Results 2022/05/12 20:05:00 GlobeNewswire
Achieved Record First Quarter Revenue Achieved Record First Quarter Revenue
Iridex to Report First Quarter 2022 Financial Results on May 12, 2022 2022/04/28 20:05:00 GlobeNewswire
MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of 2022 after the close of trading on Thursday, May 12, 2022. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.
IRIDEX (NASDAQ:IRIX) Downgraded by TheStreet to D+ 2021/12/21 16:02:42 Dakota Financial News
TheStreet downgraded shares of IRIDEX (NASDAQ:IRIX) from a c- rating to a d+ rating in a research note released on Friday, TheStreetRatingsTable reports. IRIDEX stock opened at $5.66 on Friday. The stock has a fifty day moving average of $7.26 and a two-hundred day moving average of $7.18. The company has a market capitalization of []
Cosmetic Surgery Equipment Market Size 2021 By Trends Evaluation Forecast to 2027 Candela Medical, Cutera, Lumenis, Iridex Corp, Solta Medical, Medtronic 2021/12/13 10:45:43 OpenPR
The Global Cosmetic Surgery Equipment Market Report 2021 to 2027 could be a fundamental examination of the global analysis. Trending innovation, advertise drivers, sectional declination, analysis measurements, advertise forecasts, manufacturers, and hardware merchants are all included within the substance. The
Laser Medical Devices Market Development History and Business Outlook 2027 BIOLASE, Philips, IRIDEX Corporation, LISA Laser USA, Alma Laser 2021/12/13 09:48:07 OpenPR
The Global Laser Medical Devices Market Report 2021 to 2027 could be a fundamental examination of the global analysis. Trending innovation, advertise drivers, sectional declination, analysis measurements, advertise forecasts, manufacturers, and hardware merchants are all included within the substance. The
Zacks: Brokerages Anticipate IRIDEX Co. (NASDAQ:IRIX) Will Announce Earnings of -$0.11 Per Share 2021/12/11 21:46:42 Transcript Daily
Brokerages expect that IRIDEX Co. (NASDAQ:IRIX) will report earnings per share (EPS) of ($0.11) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for IRIDEXs earnings. IRIDEX posted earnings per share of ($0.01) during the same quarter last year, which would indicate a negative year-over-year growth rate of 1,000%. The []
$14.01 Million in Sales Expected for IRIDEX Co. (NASDAQ:IRIX) This Quarter 2021/12/11 21:46:42 Dakota Financial News
Wall Street analysts expect IRIDEX Co. (NASDAQ:IRIX) to announce $14.01 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for IRIDEXs earnings, with the highest sales estimate coming in at $14.20 million and the lowest estimate coming in at $13.83 million. IRIDEX posted sales of $12.30 million during []